Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous

NCT07210671 | Recruiting

• 1 other identifier: PI2024_843_0121
• Study Type: observational
• Target: 1,576
• Locations: 1 country
• Sites: 1

Brief Summary

Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.

Conditions

Superficial Vein Thrombosis; Cancer; Venous Thrombosis

Keywords

Superficial vein thrombosis; cancer; venous thrombosis

Outcome Measures

Primary Outcomes (1)

• risk (in %) of recurrence of VTE

  risk of recurrence of VTE at 3-month follow-up in patients with cancer-associated SVT.

  at 3-month follow-up

Secondary Outcomes (19)

• association (%) between initial treatment and the risk of SVT recurrence

  at 3 months

• association (%) between initial treatment and the risk of SVT recurrence

  at 6 months

• association (%) between initial treatment and the risk of SVT recurrence

  at 12 months

• Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)

  at 12 months

• Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)

  at 3 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient with active cancer: * Cancer treatment within the last 6 months, * Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer. * The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy). * Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)

You may qualify if:

• Patient over 18
• Patient affiliated to a social security scheme
• Patient who understands French
• Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old.
• Patient with active cancer:
• Cancer treatment within the last 6 months,
• Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer.
• The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy).
• Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)

You may not qualify if:

• Patients under legal protection
• Patients with concomitant pulmonary embolism
• Patient with proximal or distal deep vein thrombosis
• Patient treated with anticoagulant therapy for another indication
• Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding.
• Patient opposed to participation in research

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (1)

CHU Amiens

Amiens, 80480, France

RECRUITING

MeSH Terms

Conditions

Neoplasms; Venous Thrombosis

Condition Hierarchy (Ancestors)

Thrombosis; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Simon SOUDET, Dr

CONTACT

33+3 22 08 80 51; soudet.simon@chu-amiens.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 30, 2025
• First Posted: October 7, 2025
• Study Start: November 10, 2025
• Primary Completion (Estimated): November 1, 2027
• Study Completion (Estimated): November 1, 2028
• Last Updated: April 14, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)